<DOC>
	<DOCNO>NCT01523990</DOCNO>
	<brief_summary>A Safety Study Evaluate Safety , Tolerability , Pharmacokinetics HCV Genotype 1 Infected Patients</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , PK Healthy Volunteers HCV Genotype 1 Infected Patients</brief_title>
	<detailed_description>A Phase 1 , Randomized , Double-Blind , Placebo-Controlled Study Healthy East Asian Caucasian Volunteers Evaluate Safety , Tolerability , Pharmacokinetics Profiles Single Multiple Ascending Oral Doses TG-2349 , Followed Dose-Ranging Study Hepatitis C Genotype 1 Infected Patients .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>East Asian Caucasian subject , male female , 18 65 year age inclusive Body mass index ( BMI ) range 19.0 30.0 kg/m2 body weight ≥ 50 kg inclusive In generally good physical mental health status basis medical history review , medical evaluation include vital sign physical examination , 12lead ECG , laboratory result screen For female , one follow criterion must fulfil : 1 . At least 1 year post menopausal , 2 . Surgically sterile , 3 . Willing use double barrier method [ intrauterine device ( IUD ) plus condom , spermicidal gel plus condom ] contraception screen 30 day last dose study drug Males must willing use reliable form contraception ( use condom partner fulfil criterion ) screen 30 day last dose study drug Willing abstain caffeine xanthinecontaining beverage , include coffee tea , alcohol , grapefruit juice , Seville oranges stayonsite period Willing able provide write informed consent Positive serological test IgM antiHAV antibody , HBsAg antiHCV antibody screen Positive ELISA test HIV1 HIV2 screen Any abnormal laboratory value screen : Hemoglobin ( Hb ) &lt; 12.0g/dL woman &lt; 13.0g/dL men , white blood cell count ( WBC ) &lt; 3,000 cells/mm3 , absolute neutrophil count &lt; 1,500 cells/mm3 , platelet count &lt; 100,000 cells/mm3 , serum creatinine ≥ 2 mg/dL , ALT AST level ≥ 2 xULN , total bilirubin ≥ 1.5 x ULN , INR ( International Normalized Ratios prothrombin time ) ≥ 1.5 xULN Any abnormal laboratory value consider clinically significant Investigator screen QTcF great 450 msec female 430 msec male screen History renal , hepatic impairment , stomach intestinal surgery resection , malabsorption syndrome History seizure , epilepsy , cardiovascular , diabetes cancer ( except basal cell carcinoma ) History family history prolong QT interval family history sudden cardiac death young age History drug allergy hypersensitivity , especially sulfa drug History evidence abuse alcohol , barbiturate , amphetamine , recreational narcotic drug use within 6 month prior first dose study drug administration Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment psychiatric illness , history suicide attempt depression Anemia blood/plasma donation within 30 day prior first dose study drug administration Pregnant breastfeeding Use tobacco nicotinecontaining product within 30 day prior first dose study drug administration Use concomitant medication , include herbal remedy , dietary supplement ( except paracetamol/acetaminophen , ibuprofen hormonal contraceptive ) within 14 day prior first dose study drug administration Received investigational drug within 30 day prior first dose study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>